SCHEMBL2366069

SCHEMBL2366069

Cc1cnc(N2CCN(C(=O)OC(C)(C)C)CC2)c(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
NR1H2 P55055 1/20 0.50
NR1H3 Q13133 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.47
MAPT P10636 2/20 0.47
TSHR P16473 1/20 0.47
POLB P06746 1/20 0.46
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.46
KIT P10721 2/20 0.46
SMO Q99835 1/20 0.46
CKS1B P61024 1/20 0.46
SKP1 P63208 1/20 0.46
SKP2 Q13309 1/20 0.46
LMNA P02545 1/20 0.45
P2RY12 Q9H244 1/20 0.44
TRPA1 O75762 2/20 0.44
GPR119 Q8TDV5 2/20 0.44
CCNK O75909 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18837988 0.89 MEN1 (0.53) MEN1KMT2ANR1H2NR1H3SMN1; SMN2
SCHEMBL2366192 0.89 MEN1 (0.55) MEN1KMT2ANR1H2NR1H3SMN1; SMN2
SCHEMBL2366741 0.87 RET (0.50) MEN1KMT2ANR1H2NR1H3SMN1; SMN2
SCHEMBL3171182 0.86 MEN1 (0.53) MEN1KMT2ANR1H2NR1H3SMN1; SMN2
SCHEMBL30903374 0.86 MEN1 (0.53) MEN1KMT2ANR1H2NR1H3SMN1; SMN2
SCHEMBL24971004 0.86 MEN1 (0.53) MEN1KMT2ANR1H2NR1H3SMN1; SMN2
SCHEMBL30903367 0.86 MEN1 (0.53) MEN1KMT2ANR1H2NR1H3SMN1; SMN2
SCHEMBL2419414 0.85 MEN1 (0.52) MEN1KMT2ANR1H2NR1H3SMN1; SMN2
SCHEMBL2417915 0.85 MEN1 (0.52) MEN1KMT2ANR1H2NR1H3SMN1; SMN2
SCHEMBL24970265 0.85 MEN1 (0.52) MEN1KMT2ANR1H2NR1H3POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240327354-A1 GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS INSTITUT PASTEUR DE LILLE (FR) 2024-10-03 US disclosed
WO-2023002011-A1 GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2023-01-26 WO disclosed
EP-2565182-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2017-10-11 EP disclosed
CN-102239152-B Novel amide derivative and use thereof as medicine MITSUBISHI TANABE PHARMA CORP. (JP) 2014-10-29 CN disclosed
US-8816079-B2 Amide derivative and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-08-26 US disclosed
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
CN-102971291-A Novel amide derivative and use thereof as medicine MITSUBISHI TANABE PHARMA CORP 2013-03-13 CN disclosed
EP-2565182-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2013-03-06 EP disclosed
US-20130040930-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-02-14 US disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
CN-102239152-A Novel amide derivative and use thereof as medicine MITSUBISHI TANABE PHARMA CORP 2011-11-09 CN disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040930-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 MEN1 2998/4885KMT2A 685/4885NR1H2 2866/4885
US-20240327354-A1 GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS ABCB11, ABCB1, ATP4B MEN1 3855/4885KMT2A 2400/4885NR1H2 4596/4885
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 MEN1 2896/4885KMT2A 800/4885NR1H2 2761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.